Indications for Treatment with Nirsevimab in Pediatric Neurology
Nirsevimab is an intravenous immunoglobulin used to prevent severe viral respiratory infections, such as the common cold and flu. Its use can be extended beyond universal immunization of the newborn, replacing the indications for palivizumab in certain neurological conditions.
Clinical Indications
- Inborn errors of metabolism.
- Neuromuscular disorders.
- Genetic syndromes with relevant respiratory problems.
- Down Syndrome.
- Those in palliative care.
Diagnostic Criteria and Clinical Algorithm
The use of nirsevimab should be considered in patients with a significant risk of severe viral respiratory infections. The clinical algorithm is based on factors such as the patient's age, neurological status, and presenting symptoms.
Practical Recommendations for Consultation
- Comprehensive individual risk assessment.
- Consider use in patients with neuromuscular diseases or genetic syndromes that increase the risk of severe viral respiratory infections.
- Perform periodic follow-up to monitor treatment effectiveness and adjust indications as necessary.
Vaccine Campaigns
Nirsevimab can be administered up to 24 months of age, corresponding to two vaccination campaigns. It is recommended to consult the attached file for more detailed information on the indications and protocols for use.